NYSE:ABTMedical Equipment
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)
In recent months, Abbott Laboratories reported Q1 2026 results that modestly exceeded sales and earnings expectations, closed its approximately US$21.00 billion acquisition of Exact Sciences to expand in cancer diagnostics, and continued to contend with extensive infant formula-related litigation and a securities class action.
At the same time, the company’s decade-high dividend yield, long record of consecutive quarterly payouts, and growing medical devices footprint contrast with...